Overview
Photopharmics develops the Celeste light therapy device, a precisely calibrated intrinsically photosensitive retinal ganglion cell (ipRGC) stimulator designed to treat Parkinson's disease non-motor symptoms.
More in Neuromodulation
Latest industry news
FDA Grants De Novo Approval to Modius Spero, Clearing First Neuromodulation Device for PTSD
2026-09-03 · Policy
Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%
2026-09-02 · Industry
Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream
2026-09-01 · Industry
FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface
2026-08-31 · Policy
Company details
Category
⚡ Neuromodulation
Location
Salt Lake City, UT, USA
Funding
Series A · $15M
Website
www.photopharmics.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →